A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
Status:
Recruiting
Trial end date:
2024-07-19
Target enrollment:
Participant gender:
Summary
LOU064 is an oral Bruton's tyrosine kinase (BTK) inhibitor. This study is an adaptive phase 2
study designed to establish safety and efficacy and characterize the dose-response of LOU064
in subjects with moderate to severe Sjögren's syndrome.